Regulatory Approval (ANDA)
Alembic Pharmaceuticals Receives USFDA Final Approval for Levothyroxine Sodium Tablets Across Multiple Strengths
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals Limited received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP across multiple dosage strengths. The approved product is therapeutically equivalent to AbbVie’s Synthroid tablets and addresses a market estimated at US$1.869 billion for the twelve months ending March 2026 according to IQVIA.
PRICE-SENSITIVE TRIGGER
Event: Alembic Pharmaceuticals received USFDA final approval for Levothyroxine Sodium Tablets USP across multiple strengths.
Type: Regulatory Approval (ANDA)
Impact: Positive
Immediate Effect: The approval strengthens Alembic’s US generics portfolio and provides access to a large thyroid therapy market in the United States.
Key Metrics:
- Approved Product: Levothyroxine Sodium Tablets USP.
- Approved Dosage Strengths:
- 25 mcg
- 50 mcg
- 75 mcg
- 88 mcg
- 100 mcg
- 112 mcg
- 125 mcg
- 137 mcg
- 150 mcg
- 175 mcg
- 200 mcg
- 300 mcg
- Reference Listed Drug (RLD): Synthroid Tablets by AbbVie.
- Estimated Market Size: US$1.869 billion.
- Market Period Considered: Twelve months ending March 2026.
- Total Cumulative ANDA Approvals Received by Alembic:
- 239 total approvals
- 220 final approvals
- 19 tentative approvals
Highlight Metric:
- Alembic secured USFDA final approval for Levothyroxine Sodium Tablets targeting a US market opportunity estimated at US$1.869 billion.
What Happened ?
Alembic Pharmaceuticals Limited announced that it received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP across multiple strengths.
The approved generic product is therapeutically equivalent to Synthroid Tablets manufactured by AbbVie.
Levothyroxine Sodium Tablets are indicated for treatment of primary, secondary, and tertiary hypothyroidism and are also used as adjunct therapy in thyroid cancer management.
According to IQVIA data, the approved product category had an estimated market size of US$1.869 billion for the twelve months ending March 2026.
With this approval, Alembic’s cumulative USFDA ANDA approvals increased to 239, including 220 final approvals and 19 tentative approvals.
Key Details
USFDA Approval & Product Details:
- Alembic received final USFDA approval for Levothyroxine Sodium Tablets USP.
- Approval covers twelve dosage strengths.
- The product is therapeutically equivalent to AbbVie’s Synthroid tablets.
- Levothyroxine is widely prescribed for thyroid hormone replacement therapy.
- The product is also used in management of thyroid cancer-related treatment protocols.
- The approval was granted under the ANDA pathway.
Note:
- The approval expands Alembic’s US generics portfolio in the endocrine therapy segment.
Market Opportunity & Commercial Relevance:
- The approved product addresses a US market estimated at US$1.869 billion.
- Market data is based on IQVIA estimates for the twelve months ending March 2026.
- Levothyroxine remains a high-volume chronic therapy medication in the US market.
- Multiple dosage approvals strengthen commercial flexibility and prescribing coverage.
- The approval improves Alembic’s ability to deepen participation in regulated US generic markets.
Note:
- The product offers access to a large and recurring chronic-care pharmaceutical market.
US Generics Portfolio Expansion:
- Alembic now has:
- 239 cumulative ANDA approvals
- 220 final approvals
- 19 tentative approvals
- The company continues strengthening its US-focused generics portfolio.
- Alembic operates vertically integrated pharmaceutical R&D and manufacturing facilities.
- The company’s manufacturing facilities are approved by multiple global regulatory authorities including USFDA.
- The approval reinforces Alembic’s regulatory execution capabilities in complex generic filings.
Note:
- Consistent ANDA approvals remain a key driver of Alembic’s long-term US generics business expansion.
Risk Analysis
Summary:
- Despite securing USFDA approval, Alembic remains exposed to pricing pressure, competitive generic launches, regulatory compliance risks, and margin volatility in the US pharmaceutical market.
Key Risks:
- US generic markets remain highly competitive with pricing erosion risks.
- Multiple-player launches may reduce commercial realization.
- Regulatory compliance remains critical for sustained US market access.
- Margin pressure may arise from distributor consolidation in the US market.
- Product commercialization timelines and market share gains remain execution dependent.
- Currency fluctuations may impact export profitability.
Worst Case Scenario:
- If aggressive generic competition leads to rapid pricing erosion, the commercial contribution from the approved product may remain below expectations.
Risk Level: Medium
Company Commentary
- Alembic confirmed receipt of USFDA final approval for Levothyroxine Sodium Tablets USP.
- The approved product is therapeutically equivalent to Synthroid tablets by AbbVie.
- The company highlighted the estimated US market opportunity of US$1.869 billion.
- Alembic stated that cumulative ANDA approvals now stand at 239.
- Management reiterated the company’s strong focus on regulated global pharmaceutical markets.
Official Exchange Filing: Alembic Pharmaceuticals Limited